Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03319940
Registration number
NCT03319940
Ethics application status
Date submitted
5/10/2017
Date registered
24/10/2017
Date last updated
11/04/2024
Titles & IDs
Public title
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Query!
Scientific title
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
Query!
Secondary ID [1]
0
0
20160323
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Small Cell Lung Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tarlatamab
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - CRS Mitigation Strategies
Experimental: Part A - Tarlatamab monotherapy
Experimental: Part C - Tarlatamab with Pembrolizumab
Experimental: Part D - Tarlatamab with additional CRS mitigation strategies
Experimental: Part E - Tarlatamab administration with 24-hour monitoring
Experimental: Part F - Tarlatamab administered in outpatient infusion centers with 8-hour monitoring
Optional wearable digital device substudy (US sites only)
Experimental: Part G - Tarlatamab additional dosing schedule
Optional wearable digital device substudy (US sites only)
Treatment: Drugs: Tarlatamab
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
Treatment: Drugs: Pembrolizumab
Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
Treatment: Drugs: CRS Mitigation Strategies
Participants will be treated with one of the CRS mitigation strategies.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with dose limiting toxicities (DLT) for all indications
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
6 months
Query!
Primary outcome [2]
0
0
Number of participants with treatment-emergent adverse events (AEs) for all indications
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
4 years
Query!
Primary outcome [3]
0
0
Number of participants with treatment-related AEs for all indications
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
4 years
Query!
Primary outcome [4]
0
0
Number of participants with clinically significant changes in vital signs for all indications
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
4 years
Query!
Primary outcome [5]
0
0
Number of participants with significant changes in electrocardiogram (ECG) for all indications
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
4 years
Query!
Primary outcome [6]
0
0
Number of participants with significant changes in physical examinations for all indications
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
4 years
Query!
Primary outcome [7]
0
0
Number of participants with significant changes in clinical laboratory tests for all indications
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
4 years
Query!
Secondary outcome [1]
0
0
Maximum observed concentration (Cmax) following intravenous administration for all indications
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
4 years
Query!
Secondary outcome [2]
0
0
Minimum observed concentration (Cmin) following intravenous administration for all indications
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
4 years
Query!
Secondary outcome [3]
0
0
Area under the concentration-time curve (AUC) over the 2 week dosing interval for all indications
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
4 years
Query!
Secondary outcome [4]
0
0
Accumulation following multiple dosing for all indications
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
4 years
Query!
Secondary outcome [5]
0
0
Half-life (t1/2) following intravenous administration for all indications
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
4 years
Query!
Secondary outcome [6]
0
0
Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Query!
Assessment method [6]
0
0
Only for parts A, D, E, F, and G
Query!
Timepoint [6]
0
0
4 years
Query!
Secondary outcome [7]
0
0
Duration of Response (DOR) for all indications
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
4 years
Query!
Secondary outcome [8]
0
0
Time to Response (TTR)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
4 years
Query!
Secondary outcome [9]
0
0
9-month Progression-Free Survival (PFS) for all indications
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
9 months
Query!
Secondary outcome [10]
0
0
9-month Overall Survival (OS) for all indications
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
9 months
Query!
Eligibility
Key inclusion criteria
- Participant has provided informed consent prior to initiation of any study-specific
activities/procedures
- Age greater than or equal to 18 years old at the time of signing the informed consent
- Histologically or cytologically confirmed SCLC. For parts A, C, D, E, F, and G:
relapsed/refractory small cell lung cancer (R/R SCLC) who progressed or recurred
following platinum-based regimen
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Participants with treated brain metastases are eligible provided they meet defined
criteria
- Adequate organ function as defined in protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of other malignancy within the past 2 years prior to first dose of tarlatamab
with exceptions
- Major surgery within 28 days of first dose tarlatamab
- Untreated (includes new lesions or progression in previously treated lesions) or
symptomatic brain metastases and leptomeningeal disease (regardless of symptomatic or
not).
- Prior anti-cancer therapy: at least 28 days must have elapsed between any prior
anti-cancer therapy and first dose of tarlatamab with the following exceptions:
participants who received conventional chemotherapy are eligible if at least 14 days
have elapsed and if all treatment-related toxicity has been resolved to Grade less
than or equal to 1; and prior palliative radiotherapy must have been completed at
least 7 days before the first dose of tarlatamab
- Participants who experienced severe, life-threatening or recurrent (Grade 2 or higher)
immune-mediated AEs or infusion-related reactions including those that lead to
permanent discontinuation while on treatment with immune-oncology agents
- Has evidence of interstitial lung disease or active, non-infectious pneumonitis
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to the first dose of
tarlatamab
- Part C only: history of solid organ transplantation or active autoimmune disease that
has required systemic treatment within the past 2 years
- Participant with symptoms and/or clinical signs and/or radiographic signs that
indicate an acute and/or uncontrolled active systemic infection within 7 days prior to
the first dose of investigational product administration
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/12/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
21/10/2025
Query!
Actual
Query!
Sample size
Target
392
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Chris OBrien Lifehouse - Camperdown
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Graz
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Salzburg
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Villejuif
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Wuerzburg
Query!
Country [18]
0
0
Hong Kong
Query!
State/province [18]
0
0
Shatin, New Territories
Query!
Country [19]
0
0
Japan
Query!
State/province [19]
0
0
Chiba
Query!
Country [20]
0
0
Japan
Query!
State/province [20]
0
0
Tokyo
Query!
Country [21]
0
0
Japan
Query!
State/province [21]
0
0
Wakayama
Query!
Country [22]
0
0
Netherlands
Query!
State/province [22]
0
0
Amsterdam
Query!
Country [23]
0
0
Netherlands
Query!
State/province [23]
0
0
Maastricht
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Jozefow
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Otwock
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Cataluña
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Madrid
Query!
Country [28]
0
0
Switzerland
Query!
State/province [28]
0
0
Lausanne
Query!
Country [29]
0
0
Switzerland
Query!
State/province [29]
0
0
Sankt Gallen
Query!
Country [30]
0
0
Taiwan
Query!
State/province [30]
0
0
Kaohsiung
Query!
Country [31]
0
0
Taiwan
Query!
State/province [31]
0
0
Taipei
Query!
Country [32]
0
0
Taiwan
Query!
State/province [32]
0
0
Taoyuan
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03319940
Query!
Trial related presentations / publications
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Amgen Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
866-572-6436
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03319940
Download to PDF